Literature DB >> 28665004

Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

Xiaoming Cheng1, Yuchen Xia1, Elisavet Serti1, Peter Daniel Block1, Michelle Chung1, Kazuaki Chayama2, Barbara Rehermann1, T Jake Liang1.   

Abstract

Hepatitis B virus (HBV) infects hepatocytes specifically and causes immune-mediated liver damage. How HBV interacts with the innate immunity at the early phase of infection, either with hepatocytes or other cells in the liver, remains controversial. To address this question, we utilized various human cell-culture models and humanized Alb-uPA/SCID mice. All these models were unable to mount an interferon (IFN) response despite robust HBV replication. To elucidate the mechanisms involved in the lack of IFN response, we examined whether HBV actively inhibits innate immune functions of hepatocytes. By treating HBV-infected cells with known inducers of the IFN signaling pathway, we observed no alteration of either sensing or downstream IFN response by HBV. We showed that the DNA innate sensing pathways are poorly active in hepatocytes, consistent with muted innate immune recognition of HBV. Upon exposure to high-level HBV, human macrophages could be activated with increased inflammatory cytokine expressions.
CONCLUSION: HBV behaves like a "stealth" virus and is not sensed by, nor actively interferes with, the intrinsic innate immunity of infected hepatocytes. Macrophages are capable of sensing HBV, but require exposure to high HBV titers, potentially explaining the long "window period" during acute infection and HBV's propensity to chronic infection. (Hepatology 2017;66:1779-1793).
© 2017 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28665004      PMCID: PMC5706781          DOI: 10.1002/hep.29348

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway.

Authors:  Pengyuan Yang; Huazhang An; Xingguang Liu; Mingyue Wen; Yuanyuan Zheng; Yaocheng Rui; Xuetao Cao
Journal:  Nat Immunol       Date:  2010-05-09       Impact factor: 25.606

Review 2.  Kinetics of the immune response during HBV and HCV infection.

Authors:  Antonio Bertoletti; Carlo Ferrari
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

3.  Impaired antiviral response in human hepatoma cells.

Authors:  P Keskinen; M Nyqvist; T Sareneva; J Pirhonen; K Melén; I Julkunen
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

4.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

5.  The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells.

Authors:  Zhiqiang Zhang; Bin Yuan; Musheng Bao; Ning Lu; Taeil Kim; Yong-Jun Liu
Journal:  Nat Immunol       Date:  2011-09-04       Impact factor: 25.606

6.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

7.  Early inhibition of hepatocyte innate responses by hepatitis B virus.

Authors:  Souphalone Luangsay; Marion Gruffaz; Nathalie Isorce; Barbara Testoni; Maud Michelet; Suzanne Faure-Dupuy; Sarah Maadadi; Malika Ait-Goughoulte; Romain Parent; Michel Rivoire; Hassan Javanbakht; Julie Lucifora; David Durantel; Fabien Zoulim
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

8.  Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.

Authors:  Nobuhiko Hiraga; Michio Imamura; Tsuyoshi Hatakeyama; Shosuke Kitamura; Fukiko Mitsui; Shinji Tanaka; Masataka Tsuge; Shoichi Takahashi; Hiromi Abe; Toshiro Maekawa; Hidenori Ochi; Chise Tateno; Katsutoshi Yoshizato; Takaji Wakita; Kazuaki Chayama
Journal:  J Hepatol       Date:  2009-09-23       Impact factor: 25.083

9.  Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages.

Authors:  Moses T Bility; Liang Cheng; Zheng Zhang; Yan Luan; Feng Li; Liqun Chi; Liguo Zhang; Zhengkun Tu; Yanhang Gao; Yangxin Fu; Junqi Niu; Fusheng Wang; Lishan Su
Journal:  PLoS Pathog       Date:  2014-03-20       Impact factor: 6.823

10.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  59 in total

1.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 2.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

3.  When viruses collide: hepatitis B virus reactivation after hepatitis C treatment.

Authors:  Ashwin Balagopal; Chloe L Thio
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 4.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

Review 5.  Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

Authors:  Marc G Ghany; Jordan J Feld; Kyong-Mi Chang; Henry L Y Chan; Anna S F Lok; Kumar Visvanathan; Harry L A Janssen
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-02-10

Review 6.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

7.  Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation.

Authors:  Bidisha Mitra; Jinyu Wang; Elena S Kim; Richeng Mao; Minhui Dong; Yuanjie Liu; Jiming Zhang; Haitao Guo
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

8.  TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.

Authors:  Audrey Boyer; Seung Bum Park; Ynto S de Boer; Qisheng Li; T Jake Liang
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

Review 9.  Virological Basis for the Cure of Chronic Hepatitis B.

Authors:  Jin Hu; Junjun Cheng; Liudi Tang; Zhanying Hu; Yue Luo; Yuhuan Li; Tianlun Zhou; Jinhong Chang; Ju-Tao Guo
Journal:  ACS Infect Dis       Date:  2018-06-25       Impact factor: 5.084

10.  Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.

Authors:  Mohamed Wehbe; Lihong Wang-Bishop; Kyle W Becker; Daniel Shae; Jessalyn J Baljon; Xinyi He; Plamen Christov; Kelli L Boyd; Justin M Balko; John T Wilson
Journal:  J Control Release       Date:  2020-11-12       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.